
RIGL stock has been on a rollercoaster ride in recent years, with its price fluctuating significantly.
The company's stock price has been affected by various factors, including its financial performance and industry trends.
RIGL's stock price has seen a significant decline in the past year, with a drop of over 50% in its value.
This decline can be attributed to the company's struggles in achieving profitability and its failure to meet analyst expectations.
Financial Performance
Rigel Pharmaceuticals's revenue in 2023 was $115.78 million, a 0.03% increase from the previous year.
The company's losses were -$25.09 million, a significant decrease of -57.16% compared to 2022.
Rigel's revenue growth has been steadily increasing, with a 71.78% growth over the past year.
Here's a breakdown of Rigel's revenue growth over the past year:
The company's financial performance is expected to continue improving, with projected revenue growth of up to 62.6% in 2024.
Key Data
Key Data is where the rubber meets the road, folks! Let's dive in and explore the essential facts that'll give you a solid understanding of a company's financial performance.
Market capitalization is a key indicator of a company's size and value. According to the data, RIGL's market cap is a respectable $382.60 million.
The number of shares outstanding can impact a company's stock price and overall financial health. RIGL has a significant number of shares outstanding, with 17.62 million shares in circulation.
Public float, on the other hand, is the number of shares available for the public to buy and sell. RIGL's public float is 17.27 million shares.
A company's beta is a measure of its volatility compared to the overall market. RIGL's beta is 1.31, indicating that it's a relatively volatile stock.
Here's a quick rundown of RIGL's key financial metrics:
These metrics provide a snapshot of RIGL's financial health and performance. Now, let's take a closer look at the company's revenue growth and EPS growth to see if it's a good investment opportunity.
Financial Performance
Rigel Pharmaceuticals's revenue was $115.78 million in 2023, a 0.03% increase from the previous year. This growth is a notable achievement, especially considering the company's revenue was $115.74 million in 2022.
You might enjoy: Jeff Bezos Has Sold 14 Million Shares of Amazon Stock
The company's financial performance has been steadily improving over the years. In 2022, Rigel Pharmaceuticals reported a loss of $25.09 million, which is a significant decrease from the previous year's losses. This improvement in financial performance is a positive sign for the company's future growth.
Here's a breakdown of Rigel Pharmaceuticals's revenue growth over the past few years:
As you can see, Rigel Pharmaceuticals's revenue growth has been inconsistent over the years, but the company has shown a steady improvement in its financial performance. The company's revenue is expected to continue growing in the future, driven by its successful execution, innovative portfolio, and strategic partnerships.
Liquidity
Liquidity is a crucial aspect of financial performance, and it's essential to understand how it affects a company's ability to meet its short-term obligations.
High liquidity means a company has a large amount of cash and liquid assets to cover its immediate expenses.
A company with low liquidity may struggle to pay its employees, suppliers, or other creditors on time.
In the "Cash Flow Management" section, we learned that a company's cash flow is the lifeblood of its liquidity.
A sudden decrease in cash flow can quickly lead to liquidity problems, making it difficult for a company to meet its financial obligations.
The "Accounts Receivable and Payable" section showed that managing accounts receivable and payable is critical to maintaining a healthy cash flow and liquidity.
Companies with high accounts receivable may struggle to collect payments from customers, further exacerbating liquidity issues.
In contrast, a company with low accounts payable may be able to negotiate better payment terms with its suppliers, improving its liquidity.
Additional reading: Stock and Flow
Capital Structure
RIGL's capital structure is a crucial aspect of its financial performance. The company's debt levels are significant, with a total debt to total assets ratio of 51.678.
This means that for every dollar of assets, RIGL has approximately 51 cents of debt. This is a relatively high ratio, indicating that the company relies heavily on debt financing.
Discover more: Is Preferred Stock Debt or Equity
The total debt to total capital ratio is 189.695, which further emphasizes the company's reliance on debt. This ratio compares the total debt to the total amount of debt and equity.
RIGL's long-term debt to total capital ratio is 164.891, which is also quite high. This suggests that a significant portion of the company's capital is tied up in long-term debt.
Here's a summary of RIGL's key capital structure ratios:
Analyst Insights
Analysts are overwhelmingly bullish on RIGL stock, with an average rating of "Buy" from 5 analysts. This suggests that they believe the stock is likely to outperform the market over the next twelve months.
The 12-month stock price forecast is $34.8, which represents a significant increase of 57.04% from the latest price. This indicates a strong potential for growth in the stock.
Here's a breakdown of the analyst ratings:
As of the last update, the majority of analysts are recommending a "Strong Buy" rating, with 2 analysts recommending this rating in each of the months from August to January.
Analyst Ratings
Analyst Ratings provide valuable insights into the potential performance of a stock. Analysts from 5 different sources have given RIGL stock an average rating of "Buy", indicating they believe it will outperform the market over the next 12 months.
The average rating is based on the opinions of 5 stock analysts who have analyzed RIGL stock. This consensus among analysts suggests a high level of confidence in the stock's potential.
In fact, the analyst rating for RIGL stock has been consistent over the past few months. Currently, the rating is "Buy", and it was also "Buy" 1 month and 3 months ago. This consistency suggests that analysts are maintaining their positive outlook on the stock.
Here's a breakdown of the current analyst ratings for RIGL stock:
Analysts have also provided a 12-month stock price forecast for RIGL stock. According to 5 analysts, the average rating is "Buy", and the 12-month stock price forecast is $34.8, which is an increase of 57.04% from the latest price.
Realizing the Promise of Its Pipeline Agents
Rigel Pharmaceuticals has shown significant growth, particularly from the acquisition of pralsetinib, leading to a 46% improvement in stock valuation since April.
R289, a dual IRAK1/4 inhibitor, demonstrated preliminary clinical activity in elderly heavily pretreated LR-MDS patients.
R289 was generally well tolerated in these patients.
RBC-TI/HI-E responses occurred in 40% of evaluable TD patients.
Rigel's pipeline includes three approved agents, including REZLIDHIA, which showed efficacy in patients with mIDH1 AML and MDS.
Initial data from the ongoing Phase 1b study evaluating R289 in LR-MDS patients is promising.
Frequently Asked Questions
Is RIGL a good stock to buy?
According to analyst ratings, RIGL stock is considered a good buy, with a strong potential to outperform the market over the next 12 months. Analysts' "Buy" rating suggests a promising investment opportunity, but it's essential to do further research before making a decision.
What is the price target for Rigel?
The average price target for Rigel Pharmaceuticals is $36.20, representing a potential 119.39% upside from its current price. Analysts' forecasts range from $23.00 to $57.00.
What does Rigel Pharma do?
Rigel Pharmaceuticals develops innovative therapies for patients with hematologic disorders and cancer. They aim to significantly improve patients' lives with their novel treatments.
Featured Images: pexels.com


